Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

At present, little is known about the molecular imaging-based response assessment of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with <sup>177</sup>Lutetium (<sup>177</sup>Lu-PSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRPC)....

Full description

Bibliographic Details
Main Authors: Fadi Khreish, Mona Wiessner, Florian Rosar, Zaidoon Ghazal, Amir Sabet, Stephan Maus, Johannes Linxweiler, Mark Bartholomä, Samer Ezziddin
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Biomolecules
Subjects:
metastatic castration-resistant prostate cancer (mCRPC)
Lutetium-177
PSMA-617
radioligand therapy
<sup>68</sup>Ga-PSMA-11 PET/CT
molecular imaging-based response assessment
Online Access:https://www.mdpi.com/2218-273X/11/8/1099

Internet

https://www.mdpi.com/2218-273X/11/8/1099

Similar Items